Trueblood Wealth Management LLC Has $624,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Trueblood Wealth Management LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,597 shares of the company’s stock after acquiring an additional 85 shares during the quarter. Trueblood Wealth Management LLC’s holdings in Zoetis were worth $624,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. International Assets Investment Management LLC boosted its position in Zoetis by 40.7% during the fourth quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock valued at $479,000 after purchasing an additional 703 shares during the last quarter. Aveo Capital Partners LLC acquired a new position in Zoetis during the fourth quarter worth $225,000. Gryphon Financial Partners LLC raised its position in Zoetis by 11.8% during the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after acquiring an additional 322 shares in the last quarter. Jump Financial LLC acquired a new stake in Zoetis in the fourth quarter valued at $339,000. Finally, Avantax Advisory Services Inc. grew its position in shares of Zoetis by 7.4% in the 4th quarter. Avantax Advisory Services Inc. now owns 9,627 shares of the company’s stock valued at $1,900,000 after acquiring an additional 662 shares during the period. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a report on Tuesday, August 27th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $217.11.

Zoetis Stock Performance

Shares of Zoetis stock opened at $189.99 on Thursday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a market cap of $86.07 billion, a PE ratio of 36.61, a price-to-earnings-growth ratio of 2.90 and a beta of 0.88. The company has a 50 day moving average of $182.22 and a 200-day moving average of $174.42. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company posted $1.41 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.